NZ541591A - Method for the treatment of cerebral ischaemia and use of erythropodietin or erythropoietin derivatives for the treatment of cerebral ischaemia - Google Patents
Method for the treatment of cerebral ischaemia and use of erythropodietin or erythropoietin derivatives for the treatment of cerebral ischaemiaInfo
- Publication number
- NZ541591A NZ541591A NZ541591A NZ54159199A NZ541591A NZ 541591 A NZ541591 A NZ 541591A NZ 541591 A NZ541591 A NZ 541591A NZ 54159199 A NZ54159199 A NZ 54159199A NZ 541591 A NZ541591 A NZ 541591A
- Authority
- NZ
- New Zealand
- Prior art keywords
- erythropoietin
- stroke
- use according
- medicament
- cerebral ischaemia
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 9
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 60
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 60
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 230000002093 peripheral effect Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000000302 ischemic effect Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000012505 colouration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 7
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 6
- 102100031939 Erythropoietin Human genes 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 102000044890 human EPO Human genes 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241001327708 Coriaria sarmentosa Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857609A DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ541591A true NZ541591A (en) | 2007-08-31 |
Family
ID=7891015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ541591A NZ541591A (en) | 1998-12-14 | 1999-12-13 | Method for the treatment of cerebral ischaemia and use of erythropodietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7514072B1 (enExample) |
| EP (1) | EP1140139B2 (enExample) |
| JP (2) | JP4750947B2 (enExample) |
| KR (1) | KR100774827B1 (enExample) |
| CN (1) | CN1187085C (enExample) |
| AT (1) | ATE253932T1 (enExample) |
| AU (1) | AU766216C (enExample) |
| BG (1) | BG65417B1 (enExample) |
| BR (1) | BR9916197A (enExample) |
| CA (1) | CA2353553C (enExample) |
| DE (2) | DE19857609A1 (enExample) |
| DK (1) | DK1140139T4 (enExample) |
| ES (1) | ES2211218T5 (enExample) |
| HK (1) | HK1042655B (enExample) |
| HU (1) | HUP0104709A3 (enExample) |
| ID (1) | ID29107A (enExample) |
| IL (2) | IL143579A0 (enExample) |
| MX (1) | MXPA01005971A (enExample) |
| NO (1) | NO330079B1 (enExample) |
| NZ (1) | NZ541591A (enExample) |
| PL (1) | PL202483B1 (enExample) |
| PT (1) | PT1140139E (enExample) |
| RO (1) | RO121409B1 (enExample) |
| RU (1) | RU2242991C2 (enExample) |
| WO (1) | WO2000035475A2 (enExample) |
| ZA (1) | ZA200104626B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| TR200103785T2 (tr) * | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| EP1423509A2 (en) * | 2001-08-30 | 2004-06-02 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use thereof |
| EP1430114B1 (en) | 2001-09-14 | 2012-01-18 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| JP2005534650A (ja) * | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| JP2006521405A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 発作回復におけるエリトロポイエチンの使用 |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| CN1897959A (zh) | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| ES2392282T3 (es) | 2004-02-13 | 2012-12-07 | Stem Cell Therapeutics Corp. | Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
| WO2007035348A2 (en) * | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| KR20080074108A (ko) * | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
| WO2007106986A1 (en) | 2006-03-17 | 2007-09-27 | Stem Cell Therapeutics Corp. | Dosing regimes for lh or hcg and epo for treatment of neurological disorders |
| CN101460188B (zh) * | 2006-06-07 | 2013-09-04 | 国立大学法人德岛大学 | 使用促红细胞生成素的局部缺血疾病的治疗 |
| LT2170279T (lt) | 2007-07-31 | 2018-03-12 | Otsuka Pharmaceutical Co., Ltd. | Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai |
| RU2446834C2 (ru) * | 2010-06-15 | 2012-04-10 | Елена Александровна Лебедева | Способ лечения пострадавших с сочетанной черепно-мозговой травмой |
| US9956265B2 (en) | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| RU2495688C1 (ru) * | 2012-03-28 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" | Способ лечения ишемии головного мозга в эксперименте |
| US9610444B2 (en) | 2013-03-15 | 2017-04-04 | Pacesetter, Inc. | Erythropoeitin production by electrical stimulation |
| KR20190052855A (ko) | 2017-11-09 | 2019-05-17 | 대한제당 주식회사 | 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| DE779362T1 (de) | 1989-12-22 | 2001-04-05 | Applied Research Systems Ars Holding N.V., Curacao | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| JP3537151B2 (ja) * | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| RU2068268C1 (ru) * | 1992-03-19 | 1996-10-27 | Учебно-научный центр Медицинского центра при Правительстве РФ | Способ профилактики церебро-васкулярных заболеваний |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| KR960701650A (ko) | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| SE520730C2 (sv) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
| US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
-
1998
- 1998-12-14 DE DE19857609A patent/DE19857609A1/de not_active Ceased
-
1999
- 1999-12-13 RU RU2001116077/14A patent/RU2242991C2/ru not_active IP Right Cessation
- 1999-12-13 WO PCT/EP1999/009864 patent/WO2000035475A2/de not_active Ceased
- 1999-12-13 HU HU0104709A patent/HUP0104709A3/hu unknown
- 1999-12-13 PL PL349335A patent/PL202483B1/pl not_active IP Right Cessation
- 1999-12-13 PT PT99966958T patent/PT1140139E/pt unknown
- 1999-12-13 US US09/868,089 patent/US7514072B1/en not_active Expired - Fee Related
- 1999-12-13 CN CNB998160474A patent/CN1187085C/zh not_active Expired - Fee Related
- 1999-12-13 JP JP2000587794A patent/JP4750947B2/ja not_active Expired - Fee Related
- 1999-12-13 DK DK99966958T patent/DK1140139T4/da active
- 1999-12-13 AT AT99966958T patent/ATE253932T1/de active
- 1999-12-13 BR BR9916197-4A patent/BR9916197A/pt not_active Application Discontinuation
- 1999-12-13 DE DE59907752T patent/DE59907752D1/de not_active Expired - Lifetime
- 1999-12-13 ES ES99966958T patent/ES2211218T5/es not_active Expired - Lifetime
- 1999-12-13 ID IDW00200101535A patent/ID29107A/id unknown
- 1999-12-13 HK HK02104485.2A patent/HK1042655B/zh not_active IP Right Cessation
- 1999-12-13 IL IL14357999A patent/IL143579A0/xx active IP Right Grant
- 1999-12-13 KR KR1020017007421A patent/KR100774827B1/ko not_active Expired - Fee Related
- 1999-12-13 RO ROA200100684A patent/RO121409B1/ro unknown
- 1999-12-13 NZ NZ541591A patent/NZ541591A/en not_active IP Right Cessation
- 1999-12-13 EP EP99966958A patent/EP1140139B2/de not_active Expired - Lifetime
- 1999-12-13 CA CA2353553A patent/CA2353553C/en not_active Expired - Fee Related
- 1999-12-13 AU AU22831/00A patent/AU766216C/en not_active Ceased
- 1999-12-13 MX MXPA01005971A patent/MXPA01005971A/es active IP Right Grant
-
2001
- 2001-06-05 IL IL143579A patent/IL143579A/en not_active IP Right Cessation
- 2001-06-06 ZA ZA200104626A patent/ZA200104626B/en unknown
- 2001-06-07 BG BG105575A patent/BG65417B1/bg unknown
- 2001-06-12 NO NO20012896A patent/NO330079B1/no not_active IP Right Cessation
-
2010
- 2010-12-20 JP JP2010283105A patent/JP2011079860A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2353553C (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| JP4754660B2 (ja) | 糖尿病の症状を治療する方法 | |
| EP2282763B1 (en) | Process for preparing supramolecular calcitonin assemblies (SCA) | |
| Pelleymounter et al. | Characteristics of BDNF-induced weight loss | |
| EP0412554B1 (en) | Sustained-release preparation for administration into brain | |
| JP2010505773A (ja) | 糖尿病性神経障害における末梢神経の形態機能的回復のための上皮増殖因子の使用 | |
| McCrystal et al. | Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl] acridine-4-carboxamide | |
| Park et al. | Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat | |
| NZ542092A (en) | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime | |
| EP0638309A1 (en) | Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications | |
| Uhler et al. | The effects of megadose methylprednisolone and U-78517F on toxicity mediated by glutamate receptors in the rat neostriatum | |
| US6589995B2 (en) | Method of inhibiting pancreatic β-cell p135 O-glycosylation | |
| JPH07505608A (ja) | インターロイキン−１阻害化合物による神経病学的状態の治療 | |
| Slim et al. | The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations. | |
| US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
| DE19732323C2 (de) | Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben | |
| DE3686684T2 (de) | Mittel zur absorptionsverbesserung von proteinen. | |
| CA2182952A1 (en) | Methods of administering n-substituted benzamides or phenothiazines | |
| US20060166885A1 (en) | Treatment and prevention of decubitus | |
| AVAKOV et al. | Pathophysiology and differentiated hyperosmolary therapy in cerebral edema in patients with craniocerebral injury. | |
| KR20030097598A (ko) | 코르티솔 길항제를 포함하는 당뇨병 타입 ⅱ의 치료용약제 | |
| CN1210737A (zh) | 一种专治早中期白血病的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |